Chicago-based CRISPR technology company Syntax Bio says it has developed tech which automates the slow, manual process of ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced it has received an ...

BACKGROUND:It Takes 2tm is a critical health initiative highlighting the importance of complete testing and early diagnosis of chronic kidney disease (CKD), particularly among those who have type 2 ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Apple Tree Partners ("ATP"), a leading life sciences venture capital firm, has announced that on December 9, 2025, certain ATP affiliates filed voluntary petitions for Chapter 11 relief in the United ...

Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

A study identified two key genes (CTNNA1 and BCL2L13) as suppressors in spread of colorectal cancer, revealing new strategies ...

A Nobel laureate, he identified an enzyme that cuts DNA, laying the groundwork for milestones in scientific research and ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in ...